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Abstract: 225 words 38 
Objectives: Proliferation of hepatocytes in vitro can be stimulated by growth factors such as 39 
epidermal growth factor (EGF), but the role of vasoactive intestinal peptide (VIP) remains 40 
unclear. We have investigated the effect of VIP on maintenance and proliferation of human 41 
hepatocytes. 42 
 43 
Materials and Methods: Human hepatocytes were isolated from liver specimens obtained 44 
from patients undergoing liver surgery. Treatment with VIP or EGF was started 24 hours 45 
after plating and continued for three or five days. DNA replication was investigated by 46 
Bromodeoxyuridine (BrdU) incorporation and cell viability detected by MTT assay. Cell 47 
lysate was analysed by western blotting and RT–PCR. Urea and albumin secretion into the 48 
culture supernatants were measured. 49 
 50 
Results: VIP increased DNA replication in hepatocytes in a dose dependant manner, with a 51 
peak response at day three of treatment. VIP treatment was associated with an increase in 52 
mRNA expression of antigen identified by monoclonal antibody Ki-67 (MKI-67) and Histone 53 
Cluster 3 (H3) genes. Western blotting analysis showed that VIP can induce a PKA/B-Raf 54 
dependant phosphorylation of extracellular signal-regulated kinases (ERK). Although EGF 55 
can maintain hepatocyte functions up to day five, no marked efffect was found with VIP. 56 
 57 
Conclusions: VIP induces proliferation of human hepatocytes with little or no effect on 58 
hepatocyte differentiation. Further investigation of the role of VIP is required to determine if 59 
it may ultimately support therapeutic approaches of liver disease.  60 
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Introduction: 61 
Hepatocyte transfusions have shown promise as an alternative  to conventional liver 62 
transplantation in treatment of some genetic disorders and acute liver failure
1,2
. These 63 
potential therapies are compromised by poor viability, rapid de-differentiation, the low 64 
proliferative capacity of primary hepatocytes in vitro
3
 and the need for high numbers of 65 
hepatocytes. In addition, there is often poor liver cell viability after cryopreservation
4
. 66 
Improving hepatocyte in vitro viability and growth is crucial for progress in their use as a 67 
replacement therapy and in drug screening. 68 
 69 
VIP is a 28-amino acid neuropeptide found largely in the brain, gastrointestinal tract and 70 
liver
5
. Moreover, VIP receptors have been characterised and purified from the liver
6,7
. 71 
Reports have shown that VIP can change the metabolic functions of rat hepatocytes, and can 72 
stimulate gluconeogenesis, ureagenesis, and inhibit glyconeogenesis
8,9
. VIP has been found 73 
to be involved in regulation of hepatic blood flow, and modulation of both innate and 74 
adaptive immune functions
10-12
. Interestingly, VIP mRNA expression is present in rat liver 75 
following partial hepatectomy (PH)
13
. Unlike Hepatic Growth Factor (HGF) and Epidermal 76 
Growth Factor (EGF), the role of VIP in liver regeneration is under-investigated. Previous 77 
reports have shown that VIP may exert bi-directional inhibitory or stimulatory effect on cell 78 
proliferation of a number of cell types. Kar et al. (1996) described a stimulatory effect of VIP 79 
alone on hepatocytes obtained from regenerated liver of rats
13
. In addition, it has been 80 
reported that VIP may have a mitogenic effect on HT29 and H9 cell lines
14,15
, while it can 81 
cause an inhibition of proliferation of human HepG2 cells
16
. 82 
 83 
The mitogen-activated protein kinase (MAPK) pathway has been reported to play a crucial 84 
role in hepatocyte replication
17
. Moreover, EGF induced proliferation of rat hepatocytes is 85 
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mainly dependant on the p44 and p42 isoenzymes (extracellular signal-regulated kinases, 86 
ERK1 and ERK2) of the MAPK pathway
18
. VIP stimulates intracellular production of cyclic 87 
adenosine 3':5'-monophosphate (cAMP) in various cell types, including hepatocytes
8
. 88 
Activation of cAMP-dependant Rap1 GTPase may be associated with either activation or 89 
inhibition of the (MAPK/ERK kinase) MEK/ERK cascade. This effect relies on the presence 90 
or absence of the serine/threonine-protein kinase B-Raf, respectively in cells
19
. Of relevance 91 
is that B-Raf kinase has been detected in liver
20
. These findings support that hypothesis that 92 
VIP may contribute in hepatocytes proliferation.  93 
 94 
In the present study, we have investigated the effects of VIP on cell proliferation, gene 95 
expression, cell signalling and function in human hepatocytes.  96 
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Materials and Methods: 97 
Isolation of human hepatocytes: 98 
Tissue samples (2-10gm) were obtained from fresh surgical macroscopically normal liver 99 
tissue resections from patients undergoing hepatectomies with informed consent (Research 100 
Ethics Committee, REC North East - Newcastle & North Tyneside 2, REC ref. 13/NE/0070). 101 
A total of 46 human liver cell preparations derived from the unaffected resection margins of 102 
the livers from 39 different donors with primary or metastatic liver tumors (24 men and 15 103 
women) were used.  Patients' ages ranged from 29 to 83 years. Hepatocytes were isolated 104 
using a two-step perfusion procedure as described previously
21
 with some modifications. 105 
Cells were plated on mouse collagen type IV gel layer 1 - 2.5µg cm
-2 
(Corning Ltd., 106 
Flintshire, UK) in William’s E medium (Thermo Fisher, Inchinnan, UK) and incubated at 107 
37°C in a humidified incubator with 5% CO2.  108 
 109 
5-Bromo-2’-deoxyuridine (BrdU) DNA incorporation assay: 110 
EGF (Sigma, Gillingham, UK) at 5, 10 and 20ng ml
-1
 or VIP (Sigma) at 10
-8
, 10
-7
 or 10
-6
M 111 
was added 24 hours following cell seeding. Hepatocytes were incubated with BrdU (10µg ml
-
112 
1
, Sigma) for 2 hours at 37°C. DNA-integrated BrdU was detected by rat anti-BrdU antibody 113 
(Bio-Rad, Hertfordshire, UK) and subsequently donkey anti-rat IgG-Alexa 488 (Thermo 114 
Fisher). Nuclei were stained with 4'-6-diamidino-2-phenylindole, DAPI (Sigma). Using 115 
fluorescence microscopy, numbers of BrdU
+ 
and
 
DAPI
+
 cells were determined in 6 different 116 
high power fields per well. 117 
 118 
Measurement of lactic dehydrogenase (LDH): 119 
Equal volumes of 200mM Tris (hydroxymethyl) aminomethane (Tris) pH 8, 50mM Lithium 120 
lactate, freshly prepared substrate solution [100µl P-Iodonitrotetrazolium Violet, INT (33mg 121 
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ml
-1
 in dimethyl sulfoxide (DMSO) + 100µl, Phenazine methosulfate, PMS (9 mg ml
-1
) + 2.3 122 
ml β-nicotinamide adenine dinucleotide (NAD) hydrate (3.74 mg ml
-1
)] and samples or 123 
positive control (5µg ml
-1
 L-Lactic Dehydrogenase from bovine heart, Sigma) were loaded 124 
into an assay plate. The Vmax was measured at 490nm for 10min in a SpectraMax® Plus 384 125 
Microplate Reader (Molecular Devices, Wokingham, UK) and LDH activity (U ml
-1
) was 126 
calculated. 127 
 128 
Viability and Proliferation Assays: 129 
Viability was determined using a colourimetric MTT assay (Sigma) and Quick Cell 130 
Proliferation Assay kit II (Abcam, Cambridge, UK) were used according to manufacturers’ 131 
instructions. 132 
 133 
Polymerase Chain Reaction (PCR) and Real time PCR (rt-PCR): 134 
RNA was extracted using a RNeasy® kit (Qiagen, Crawley, West Sussex, UK) following the 135 
manufacturer’s instructions. Complementary DNA (cDNA) was synthesised using a Primer 136 
Design Precision nanoScript 2 reverse transcriptase kit (Millbrook, Southampton, UK) 137 
according to the manufacturer’s instructions in a MasterCycler® 480 thermocycler 138 
(Eppendorf, Hamburg, Germany). The rt-PCR Primers were designed using the ProbeFinder 139 
software version 2.5 (Lifescience.roche.com) and oligonucleotide primers for albumin, 140 
Antigen Identified By Monoclonal Antibody Ki-67 (MKI-67), Histone Cluster 3 (H3) were 141 
obtained from Eurofins MWG/operon (Ebersberg, Germany) (Supplementary data 1). VIP 142 
and pituitary adenylate cyclase-activating polypeptide receptor-1 (VPAC1) and EGF receptor 143 
(EGFR) mRNA expression was assessed using GoTaq® Hot Start Polymerase (Promega UK 144 
Ltd, Southampton, UK) according to manufacturer’s instructions. PCR products were 145 
visualized on 2% agarose gel, band densities were measured and normalised to that of 146 
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Glycerinadehyde-3-Phosphate-Dehydrogenase, GAPDH using a ChemiDoc™ imaging 147 
system (Bio-Rad). The qPCR was performed using a SYBR green Mastermix buffer (Primer 148 
Design) in an A&B 7900HT Fast Real-Time PCR System thermocycler (Applied Biosystems, 149 
CA, USA). The Ct values were normalized to the GAPDH and calibrated to untreated cells. 150 
The fold change of mRNA expression was calculated according to the ∆∆Ct method.  151 
 152 
Detection of Phospho-p44/42 MAPK (Erk1/2) and VPAC1 in hepatocytes using Western 153 
Blotting: 154 
Hepatocytes were serum starved for 24 hours prior to incubation with EGF (20 ng ml
-1
) or 155 
VIP (10
-6
 M). The B-RAF inhibitor, SB-590885 and the PKA inhibitor, Rp-cAMP 156 
triethylammonium salt (Rp-cAMPS) were used. Cells were lysed using TruPAGE™ LDS 157 
Sample Buffer (Sigma) with phosphatase and protease inhibitors. Protein concentrations were 158 
measured and separated in a TruPAGE® 10% precast gels (Sigma) under reducing 159 
conditions, then transferred to nitrocellulose membranes. The membranes were probed with 160 
rabbit anti-human Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody or rabbit anti-161 
human p44/42 MAPK (Erk1/2) antibody (New England Biolabs, Hertfordshire, UK), 162 
followed by goat anti-rabbit-horseradish peroxidase (HRP) (DakoCytomation, 163 
Cambridgeshire, UK). Reactive bands were detected using the Luminata Forte Western HRP 164 
substrate (Millipore UK Ltd., Hertfordshire, UK). In another experiment, the level of VPAC1 165 
protein expression in untreated or VIP (10
-6
M) treated hepatocytes, was investigated using a 166 
rabbit polyclonal anti VPAC1 (Abcam) and followed by goat anti-rabbit-horseradish 167 
peroxidase (HRP) (DakoCytomation). 168 
 169 
cAMP Direct Immunoassay: 170 
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Levels of cAMP in hepatocytes 24 h following cell seeding and at day 3 or 5 following 171 
stimulation with 10
-6
M VIP treatment were detected using a cAMP direct immunoassay 172 
(Abcam) according to the manufacturer’s instructions. cAMP concentrations (µM) were 173 
determined and corrected to total proteins concentrations in samples (µg). 174 
 175 
Albumin ELISA and Urea concentration assay: 176 
Albumin and urea concentrations in the supernatant of hepatocytes cultures were determined 177 
using the ELISA DuoSET
®
 kit for human albumin (R&D Systems, Oxfordshire, UK) and the 178 
QuantiChrom™ urea assay kit (QuantiChrom, BioAssay Systems, Hayward, CA) 179 
respectively, according to the manufacturer’s instructions. 180 
 181 
Statistics: 182 
Two-way analysis of variants (ANOVA) followed by Fisher's least significant difference 183 
(LSD) multiple comparisons tests were performed using GraphPad Prism version 7.7.1 for 184 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. Data has been 185 
represented by Mean ± standard error of the mean (SEM) or standard deviation (SD) as 186 
indicated. P < 0.05 was taken as significant.  187 
 188 
For further details regarding the materials and methods, please refer to the supplementary 189 
data 1.  190 
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Results: 191 
Stimulation of DNA replication in hepatocytes by VIP: 192 
EGF at high concentrations such as 50ng ml
-1
, has been reported to be responsible for an 193 
increase in [3H] methylthymidine incorporation in rat hepatocytes. The response to EGF 194 
maximised at 24 hour and continued with persistent exposure
22
. In the current work, 195 
proliferation of human hepatocytes was investigated by detecting BrdU incorporation (Figure 196 
1A). Herein, EGF resulted in an increase of BrdU positive cells at concentrations of 10ng ml
-
197 
1
 (a mean of 1.3 ± SD 0.9 fold) and 20ng ml
-1
 (a mean of 1.8 ± SD 1.4 fold) at day 3 (Figure 198 
1B), and this effect was continued at day 5 of treatment, 10 ng ml
-1
 (a mean of 1.5 ± SD 0.5 199 
fold) and 20 ng ml
-1
 (a mean of 1.7 ± SD 0.5 fold) (Figure 1C). Interestingly, VIP stimulated 200 
proliferation of human hepatocytes in a dose dependant manner at day 3 up to a mean of 3.2 201 
± SD1.1 fold at 10
-6
M (Figure 1D). However, a decline of hepatocyte response to VIP was 202 
observed at day 5 (a mean of 1.2 ± SD 0.6 fold up to 10
-6
M) (Figure 1E). Similarly, EGF 203 
addition was associated with a rise in total cell numbers at day 3; 10ng ml
-1
 (a mean of 1.4 ± 204 
SD 1.1 fold) and 20ng ml
-1
 (a mean of 1.9 ± SD 1.7 fold) and day 5; 10ng ml
-1
 (a mean of 1.7 205 
± SD 0.4 fold) and 20 ng ml
-1
 (a mean of 1.7 ± SD 0.3 fold). VIP at day 3 resulted in an 206 
increase of total cells by a mean of 2.2 ± 0.9 fold at 10
-7
M and 3.4 ± SD 1.4 fold at 10
-6
M. 207 
The drastic decrease in hepatocyte response to VIP at day 5 raised a concern about changes in 208 
cell viability and status, and was investigated further.  209 
 210 
VIP treatment has a limited effect on hepatocyte survival in vitro: 211 
Effects of EGF or VIP on hepatocyte integrity was tested by measuring LDH release in the 212 
cell culture supernatants. In the first 24 hours following cell extraction, LDH activity was 213 
high (a mean of 0.90 ± SD 0.29 U ml
-1
) (Figure 2A), which may be a result of the isolation 214 
process or spontaneous activation of hepatocyte apoptosis
23,24
. A dramatic decrease in LDH 215 
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levels was observed in the following 24 hours (a mean of 0.14 ± SD 0.16 U/ml). This may 216 
have been caused by washout of old medium containing dead and apoptotic cells. No further 217 
change in LDH activity was observed up to day 5. Treatment of hepatocytes with EGF 218 
resulted in a minimal change in LDH activity in the supernatants at day 1 compared to 219 
untreated cells. A decrease in LDH activity was observed at days 3 and 5 at various 220 
concentrations of EGF (Figure 2B). When VIP was added to the medium, no change in LDH 221 
activity was observed at day 1 or 3 of treatment (Figure 2C). At day 5, cells treated with VIP 222 
showed a marked increase in LDH levels, with approximately 2, 8 and 10 fold changes at 10
-
223 
8
M, 10
-7
M and 10
-6
M of VIP respectively. There was also a rise in LDH activity when both 224 
agents were added together to the hepatocyte culture medium (data not shown). 225 
 226 
The metabolic activity of the cell was assessed using the MTT assay. At day 3, EGF showed 227 
a marked improvement in cell viability (Figure 2D) and VIP treatment was associated with a 228 
concentration dependant increase in hepatocyte metabolic activity, peaking at a concentration 229 
of 10
-6
M (Figure 2E). Results showed low metabolic activity of primary human hepatocytes 230 
after day 5 of cell seeding, irrespective of the addition of EGF or VIP. This result may reflect 231 
cell loss. 232 
 233 
Previous results have shown that the support of hepatocyte survival was lacking when VIP 234 
was used alone and cells have entered a late phase of death or apoptosis. In order to address 235 
this, we have tested DMSO as an agent which may prevent this deterioration of cell viability 236 
and as reported, can maintain hepatocyte differentiation and improve liver-specific 237 
functionality
25
. DMSO alone  induced cell death as compared to medium alone, however 238 
addition of 2% DMSO to culture medium was associated with the restoration of the 239 
hepatocyte response to EGF and the VIP mitogenic effect at day 5 of treatment (Figure 3A 240 
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and 3B). In addition to hepatocytes loss, the noticeable decrease in the effect of VIP by day 5 241 
and a change in expression of VIP receptors may contribute to hepatocyte resistance VIP. To 242 
test this possibility mRNA expression of VPAC1, the most abundant VIP receptor in the 243 
liver, was investigated using a semi-quantitative RT-PCR technique
26
. In untreated 244 
hepatocytes, level of mRNA expression of VPAC1 or EGFR did not change significantly at 245 
day 3 (Figure 3C).  However, at day 5 cells expressed lower levels of EGFR mRNA which is 246 
a phenomenon that has been reported previously
27
 but VPAC1 mRNA expression did not 247 
show any change. Western blotting revealed several forms of VPAC1 in human hepatocytes 248 
at molecular weights of ~250, ~100 and ~52 kDa (Figure 3D), as described previously
28
. 249 
During hepatocytes culture, VPAC1 protein expression did not show marked changes, but 250 
VIP treatment was associated with a marked decrease in VPAC1 gene mRNA expression at 251 
day 5 of cell culture (Supplementary Figure 1). The level of VPAC1 activation has previously 252 
been assessed by measuring intracellular cAMP concentrations. Interestingly, exposure of 253 
VPAC1 to VIP at a concentration of 10
-6
M at 24 hours following cell seeding was found to 254 
stimulate production of cAMP by hepatocytes as compared to untreated cells (mean 255 
concentration 5.96 µM/µg of protein ± SEM 0.64 versus 4.18 ± 0.60  respectively, P = 256 
0.0029) (Figure 3E). Production of cAMP as a response to VIP continued but to a lesser 257 
extent until day 3 of hepatocyte culture (mean of 5.90 µM/µg of protein ± 0.77 and 4.95 ± 258 
0.97 respectively, P = 0.0761). Notably, constitutive cAMP showed a lower concentration at 259 
day 5 of cell culture in untreated cells (a mean of 3.85 ± SEM 0.84 µM/µg of protein) and 260 
VPAC1 receptors did not show as clear a response to VIP as that seen at early time points 261 
(4.52 ± 0.69 µM/µg of protein). Taken together, these finding may suggest a change in 262 
receptor functionality over time.  263 
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Expression of proliferation-associated genes was induced by VIP treatment: 264 
Expression of the active cell cycle marker, MKI-67
29
 and the mitotic marker, H3
30
 genes 265 
were studied using quantitative rt-PCR. EGF alone induced a six-fold increase in mRNA 266 
expression of MKI-67, most significantly at day 3 of treatment at concentrations up to 10ng 267 
ml
-1
 (Figure 4A). In addition, EGF treatment resulted in up to a four-fold increase in 268 
expression of H3 mRNA by day 3 of treatment, most noticeably at 20ng ml
-1
 EGF (Figure 269 
4B). Addition of VIP to cultured hepatocytes were associated with a two-fold increase in 270 
MKI-67 gene expression at day 3, rising to four-fold at day 5 of treatment at a concentration 271 
of 10
-6
M (Figure 4C).  Similarly, VIP induced a concentration dependant increase in 272 
expression of H3 at days 3 and 5 (Figure 4D). Although the combination of EGF and VIP 273 
was associated with a considerable increase in expression of MKI-67 at day 5, there was no 274 
difference compared to either EGF or VIP alone (Figure 4E). The presence of EGF and VIP 275 
together in the culture medium had little effect on expression of H3 at day 3 (Figure 4F). 276 
 277 
Production of Phospho-p44/42 MAPK (Erk1/2) in VIP treated hepatocytes: 278 
Binding of VIP to its receptors initiates cAMP production and subsequent protein kinase A 279 
(PKA)
31
. A PKA-dependent phosphorylation of the GTPase Rap1 resulted in stimulation of 280 
ERKs in the presence of B-Raf in cells such as hepatocytes
19
. EGF at 20ng ml
-1
 stimulated 281 
phosphorylation of ERK as early as 10 minutes, after which activation declined with time 282 
(Figure 5A). Interestingly, VIP was found to increase pERK following 10 minutes incubation 283 
with hepatocytes.  However, ERK activation increased further up to 60 minutes (Figure 5B). 284 
In addition, VIP stimulation of freshly isolated hepatocytes failed to elicit phosphorylation of 285 
ERK (data not shown). Both agents did not preferentially activate either pERK 1 or 2. Pre-286 
incubation of human hepatocytes with 5µM of SB-590885 (SB), a B-RAF inhibitor prior to 287 
treatment or Rp-cAMPS (cAMP inhibitor) at 500µM was associated with inhibition of VIP 288 
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induced pERK (Figure 5C and 5D). Interestingly, SB was found to preferentially block ERK2 289 
phosphorylation to a greater extent than ERK1. Whereas inhibition of cAMP mobilization 290 
with Rp-CAMP inhibitor blocked both ERK1 and ERK2. 291 
 292 
VIP treatment does not support human hepatocytes specific functions: 293 
Albumin gene expression was suppressed initially, but recovered by day 3 of incubation with 294 
EGF at a concentration of 5 ng ml
-1
 and markedly increased at day 5 with concentrations up 295 
to 5 to 20 ng ml
-1
 (Figure 6A). Conversely, VIP had no marked effect on albumin gene 296 
expression in human hepatocytes in this model (Figure 6B). When EGF and VIP were 297 
combined together, the stimulatory effect of EGF on albumin gene expression was 298 
significantly lower than that of EGF alone (Figure 6C).  299 
 300 
Albumin levels in the supernatants dropped from a mean of 75.14 ± SD 22.13ng ml
-1
 in the 301 
first 24 hours following hepatocyte seeding to a mean of a mean of 40.24 ± SD 16.82 ng ml
-1
 302 
at day 2 and no marked change was observed subsequently. EGF stimulated production of 303 
albumin from liver cells in a concentration dependent manner as compared to the untreated 304 
control at day 1 of treatment yielded a mean of 120.91± SD 79.91 ng ml
-1
 which continued up 305 
to day 5 of treatment to reach a mean of 152.80 ± SD 87.20 ng ml
-1
 with 20ng ml
-1
 EGF 306 
(Figure 6D). At day 3, there was an increase in albumin production up to a mean of 66.9 ± 307 
SD 76.83 ng ml
-1
 from hepatocytes cultured in the presence of 10
-6
M VIP (Figure 6E). When 308 
both agents were added together, the stimulatory effect of EGF was inhibited (Figure 6F). 309 
When both agents were added sequentially, an inhibitory effect of VIP on EGF stimulated 310 
albumin production was observed (Supplementary Figure 2). Urea production from 311 
hepatocytes was dramatically decreased during the 24 hours following cell plating from a 312 
mean of 3.01 ± SD 0.38 mg dL
-1
 to a mean of 0.80 ± SD 0.98 mg dL
-1
, but partial recovery 313 
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was observed at day 3 and 5 (a mean of 1.26 ± SD 0.37 mg dL
-1
 and 1.10 ± SD 0.36 mg dL
-1
 314 
respectively). EGF increased urea production on the first day of hepatocyte culture compared 315 
to untreated cells (a mean of 1.31 ± SD 0.23 mg dL
-1
 at 10 ng ml
-1
 EGF), but this effect 316 
disappeared with time (Figure 6G).  However, 10
-7
M VIP resulted in a limited increase (a 317 
mean of 1.53 ± SD 0.51 mg dL
-1
) in urea production at day 3 as compared to control (Figure 318 
6H) and adding VIP to EGF abolished the effect of EGF on urea production in cultures 319 
hepatocytes (Figure 6I).  320 
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Discussion: 321 
Our findings have shown that EGF or VIP alone has the ability to induce DNA synthesis in 322 
cultured human hepatocytes and to stimulate expression of genes that may be involved in cell 323 
proliferation. Interestingly, EGF was able to maintain hepatocyte proliferation further up to 324 
day 5 whilst VIP did not. In addition, VIP was found to stimulate phosphorylation of ERK1 325 
and 2 protein kinases. However, unlike EGF, VIP has a limited effect on hepatocyte function 326 
in vitro. 327 
 328 
Hepatocytes move from G0 to G1 phase of cell cycle spontaneously during isolation 329 
process
32
 and progress further towards and stop at a restriction point in mid-late G1 phase 330 
usually 24 and 48 h after plating
22
. Onward movement to S phase is dependent on growth 331 
factors such as EGF
33
. In agreement with that, we have demonstrated that EGF stimulated 332 
DNA synthesis when added 24 h following hepatocytes seeding. Strikingly, we observed a 333 
comparable effect with VIP which disagree to that previously reported by Kar et al
13
.  The 334 
outcome of proliferative stimuli is related to the cell cycle. A few hours following isolation, 335 
VIP can facilitate entry of cells into G1 phase but it did not encourage them to pass the 336 
restriction point
34
. This effect could increase the number of cells at susceptible to the 337 
mitogenic effect of EGF. These findings might explain why VIP alone failed to stimulate 338 
DNA synthesis in hepatocytes but may potentiate the effect of  EGF on cell proliferation at 339 
this early time point
13,22,35
. We found that VIP did activate MAPK at this early time which 340 
consistent with that has been reported
35
. The underling mechanism could involve activation 341 
of p70 ribosomal S6 protein kinase (p70S6k) activity,  cyclin D3-cyclin-dependent kinase 342 
(CDK)-4 assembly or a CDK2/cyclin C-dependent inhibitory phosphorylation of the 343 
transcription factor LSF (late simian virus 40 factor) at serine 309
36-38
.  344 
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As we have shown, later in culture VIP or EGF stimulated formation of pERK which has 345 
been described previously
18,39
. This effect was found to be closely related to induction of 346 
hepatocyte proliferation
17
 and may involve an MAPK-dependent reactivation 347 
phosphorylation of LSF at serine 291 which could be essential for cell cycle progression to S 348 
phase
40
. Dependence of VIP induced ERK activation on B-Raf kinase could support our 349 
hypothesis that VIP alone is able to induce hepatocyte proliferation, but VIP exerted an 350 
inhibitory effect on EGF (Figure 7). In accordance with these results, it has been reported that 351 
high levels of cAMP could result in a decrease in EGF-dependent MAPK production and loss 352 
of its DNA stimulatory effect
35
. In addition, several reports have shown that cAMP-353 
dependent PKA is able to phosphorylate EGFR on serine residues which results in decrease 354 
in tyrosine kinase activity and EGFR auto-phosphorylation induced by EGF
41,42
. Moreover, 355 
cAMP-GEFs can directly inhibit Raf-1 by phosphorylation at ser259 or indirectly by a PKA-356 
dependent activation of the Raf-1 inhibitor, Akt (protein kinase B, PKB)
43,44
. This interaction 357 
could explain the reported VIP inhibitory effect on HepG2 proliferation. HepG2 survival and 358 
proliferation is depending on the presence of FBS in medium
45,46
. VIP has been shown to 359 
inhibit HepG2 proliferation through a cAMP – dependent  signal transducers and activators 360 
of transcription-3 (STAT-3) pathway inhibition
16
, the pathway that can be stimulated by 361 
growth factors which present in FBS. 362 
 363 
The DNA synthesis in primary hepatocytes started early in culture and maximised at day 3, 364 
with expression of activated transcriptional regulators for EGF and ERK pathway
47
, but 365 
decreased afterwards even in the presence of EGF
13,48
. Following day 3 of culture, substantial 366 
hepatocyte death has been reported and the remaining cells may become flattened and 367 
polykaryotic or smaller and apoptotic
3
. We have noticed that, at day 5 of EGF treatment, 368 
there was a lower number of living hepatocytes, and that the remaining cells replicated, but to 369 
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a lower extent.  This is in agreement with previous findings to that has been reported 370 
before
33,49
.  371 
In our model, VIP did not show any change in hepatocyte proliferation, consistent with 372 
previous work
13
. Notably, the cells which proliferated under theeffect of VIP mostly died by 373 
day 5 of treatment and VIP did not markedly increase DNA synthesis in the remaining cells.  374 
The lack of support of the differentiated state of hepatocytes with VIP treatment was 375 
observed from the albumin production and urea secretion at day 5, a finding that has been 376 
previously reported
9
. Interestingly, MKI-67 and H3 mRNA expression in hepatocytes showed 377 
a tendency to increase at day 5 of treatment while albumin expression decreased with time, 378 
which may be an indication of a loss of differentiation. 379 
 380 
The dramatic change in hepatocyte response to VIP could be a consequence of changes in 381 
VIP receptors expression. We found that hepatocytes did not show such a change in 382 
expression of VPAC1 during culture time course. However, VIP failed to induce cAMP 383 
production in hepatocytes at day 5 of cell culture, which suggests an alteration of receptor 384 
signaling response. Indeed, the interaction between VIP and its receptors in proliferating 385 
hepatocytes is not completely understood. In rat liver 3 days after PH, the maximal response 386 
of VIP was reduced as a result of low number of receptors and changes in the receptor 387 
structure
50
. In addition, the decrease in VIP receptors sensitivity could be a result of high 388 
expression of VIP in proliferating liver
13
. Moreover, VPAC1 harbours several potential N-389 
glycosylation sites which are critical for VIP binding
51
 and receptor delivery to plasma 390 
membrane
52
. An alteration in  N-glycosylation of proteins has been reported in de-391 
differentiated rat hepatocytes
53
, and could explain the decreased in VPAC1 response to VIP, 392 
but this possibility needs further investigations. In addition, we have demonstrated that 393 
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addition of high concentration of VIP was associated with downregulation of VPAC1, the 394 
phenomenon that has been reported with VIP with other cell types
54,55
. 395 
Our findings have demonstrated that VIP alone was able to induce proliferation of adult 396 
human hepatocytes when added 24 hours following hepatocyte platting and this effect may be 397 
PKA/B-Raf–ERK dependent. VIP exerts an inhibitory effect on EGF signaling pathway at 398 
this time point of cell cycle. Stimulation of the VIP pathway may aid hepatocyte proliferation 399 
in vitro. 400 
 401 
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Figures’ Legends: 554 
Figure 1 Hepatocyte proliferation was stimulated by EGF or VIP.  (A) Representative 555 
images of hepatocytes treated with either EGF (20 ng ml
-1
) or VIP (10
-6 
M) for 3 days. DNA 556 
incorporation of BrdU was determined (Green) and DAPI (Blue) was used as a nuclear 557 
counter stain. (B - E) The effects of EGF or VIP were demonstrated on total and proliferating 558 
cell numbers. n = 3 different donors per condition. P values shown in the graph are for 559 
comparison to hepatocytes maintained on medium alone. * P<0.05, ** P<0.005, *** 560 
P<0.0005, **** P <0.0001. Mean ± SEM. Two-way ANOVA followed by Fisher's least 561 
significant difference (LSD). 562 
 563 
Figure 2 Hepatocyte viability with EGF or VIP. (A) LDH activity (U ml
-1
) in supernatants 564 
of untreated human hepatocytes with time course. (B) LDH release (expressed as percentage 565 
of total LDH activity) in supernatants of human hepatocytes treated with EGF or (C) VIP at 566 
previous concentrations following day 1, 3 and 5 of treatments. n = 3 different donors per 567 
condition. P values shown in the graph are for overall comparison with hepatocytes at day 0 568 
(A) or untreated control (B and C). * P<0.05, ** P<0.005, *** P<0.0005, **** P<0.0001. 569 
(D) Viable cells were detected following addition of EGF (5, 10 or 20 ng ml
-1
) or (E) VIP 570 
(10
-8
, 10
-7
 or 10
-6 
M) treatment for 3 or 5 days by MTT assay. A, Absorbance. n = 3 different 571 
donors per condition. P values shown in the graph are for overall comparison between 572 
hepatocytes at day 3 and 5. Mean ± SEM. Two-way ANOVA followed by Fisher's LSD. 573 
 574 
Figure 3 The effect of DMSO on cell response to VIP and VIP and pituitary adenylate 575 
cyclase-activating polypeptide receptor-1 (VPAC1) expression and activation in 576 
hepatocytes. (A and B) Hepatocytes were treated with either EGF (5, 10 or 20 ng ml
-1
) or 577 
VIP (10
-8
, 10
-7
 or 10
-6 
M), 2 % DMSO was added at day 3 and cell proliferation was 578 
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investigated at day 5 using the WST-1 Quick Cell Proliferation Assay kit II (Abcam). n = 3 579 
different donors per condition. P values shown in the graph are for comparison at individual 580 
concentrations and overall comparison with hepatocytes maintained in medium without 581 
DMSO. (C) Band density analysis (fold change) of VPAC1 and Epidermal Growth Factor 582 
Receptor (EGFR) mRNA of gene expression on 2% agarose gel in non-treated cells 583 
following 1, 3 or 5 days of hepatocyte culture (6 donors), (D) VPAC1 protein expression as 584 
detected in hepatocytes by western blotting techniques at day 3 and 5 of hepatocyte culture, a 585 
representative blot of 3 independent experiments. Molecular weights were indicated for 586 
VPAC1 isoforms. (E) Effect of VIP (10
-6
 M) on cAMP concentrations (µM µg
-1
 of protein) in 587 
hepatocytes with time course control (ctrl.). n = 3. * P<0.05, ** P<0.005. Mean ± SEM. 588 
Two-way ANOVA followed by Fisher's LSD.  589 
 590 
Figure 4 Expression of Monoclonal Antibody Ki-67 (MKI-67) and Histone Cluster 3 591 
(H3) genes in human hepatocytes cultured in the presence of EGF or VIP. Expression of 592 
mRNA was quantified by qPCR at days 1, 3 and 5 of EGF (5, 10 or 20 ng ml
-1
) or VIP (10
-8
, 593 
10
-7
 or 10
-6
 M). (A – D) Concentration dependant effects of EGF or VIP, and (E and F) the 594 
effect of EGF (20 ng ml
-1
) or VIP (10
-6
 M) or a combination of both. n = 3 different donors 595 
per condition. P values shown in the graph are for comparison at individual concentrations 596 
and overall comparison with hepatocytes at day 1. * P<0.05, ** P<0.005, *** P<0.0005. 597 
Mean ± SEM. Two-way ANOVA followed by Fisher's LSD. 598 
 599 
Figure 5 Phosphorylation of ERK in EGF or VIP-treated human hepatocytes analysis 600 
using western blotting. (A) Hepatocytes treated with either EGF (20 ng ml-1) or (B) VIP (10
-6
 601 
M) and analysed by western blotting at indicated time points. (C) The effects of downstream 602 
pathway inhibitors was investigated using 2.5 - 10 µM of SB-590885 (SB) or (D) 500 µM of 603 
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Rp-cAMPS. Hepatocytes were incubated with inhibitors for 1 h prior to addition of EGF or 604 
VIP for another 1 h. n = 4 with different donors.  605 
 606 
Figure 6 Expression and production of albumin, and urea from human hepatocytes 607 
cultured with EGF and VIP. Albumin gene mRNA expression at days 0, 1, 3 and 5 of (A) 608 
EGF (5, 10 or 20 ng ml-1) or (B) VIP (10
-8
, 10
-7
 or 10
-6
 M) treatments, and (C) the effects of 609 
either EGF (20 ng ml-1), VIP (10
-6
 M) or combination of both were determined. P values 610 
shown in the graph are for comparison at individual concentrations and overall comparison 611 
with hepatocytes at day 1. (D – F) Albumin (ng ml-1) and (G – I) urea (mg dL
-1
) 612 
concentrations in supernatants of cultured hepatocytes with EGF, VIP or both were 613 
determined. n = 3 different donors per condition. P values shown in the graph are for 614 
comparison with hepatocytes at day 0 or with untreated cells. * P<0.05, ** P<0.005, *** 615 
P<0.0005, **** P<0.0001. Mean ± SEM. Two-way ANOVA followed by Fisher's LSD. 616 
 617 
Figure 7 A schematic diagram for VIP and EGF signaling in hepatocytes. Late in culture, 618 
binding of VIP with the G-protein coupled VIP receptor type 1 (VPAC1) activates 619 
intracellular adenylyl cyclase (AC) resulting in cAMP production and the following protein 620 
kinase A (PKA) activation. Subsequently, phosphorylated Rap-1 can activate B-Raf and 621 
thereby, stimulate the mitogen-activated protein kinase (MAPK) / extracellular signal-622 
regulated kinase (ERK) kinase, MEK/ERK cascade. Phosphorylation of ERK1/2 results in 623 
stimulation of cell proliferation and induces mRNA expression the proliferation-associated 624 
genes, the monoclonal antibody Ki-67 (MKI-67) and Histone Cluster-3 (H3) genes. EGF 625 
interaction with its receptors, EGFR results in a Ras/Raf dependent activation of MEK, 626 
induction of cell proliferation and improvement of cell functions. VIP-activated Rap-1 may 627 
block EGF signaling through inhibition of Ras/Raf activation. VIP signaling can be inhibited 628 
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by the B-RAF inhibitor, SB-590885 and PKA inhibitor, Rp-cAMP triethylammonium salt 629 
(Rp-cAMPS). 630 
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Materials and Methods: 28 
Isolation of human hepatocytes: 29 
Tissue samples (2-10gm) were obtained from fresh surgical macroscopically normal liver 30 
tissue derived from resections from patients undergoing hepatectomies. Experimental 31 
procedures were performed according to the Health Research Authority (HRA), Research 32 
Ethics Committee (REC) North East - Newcastle & North Tyneside 2 (REC ref. 13/NE/0070) 33 
with informed consent. A total of 46 human liver cell preparations from 39 different donors 34 
have liver primary or secondary metastatic tumors (24 men and 15 women) were used. 35 
Patients' ages ranged from 29 to 83 years. Hepatocytes were isolated using a two-step 36 
perfusion procedure as described previously
1
 with some modifications. Liver tissue was 37 
washed for 10 minutes with a calcium chelating buffer [1x Hanks' balanced salt solution 38 
(HBSS), 25 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) and 0.5mM 39 
Ethylene glycol-bis (2-aminoethylether)-N,N,N′,N′-tetra acetic acid (EGTA)]. Specimens 40 
were digested using 0.05% collagenase in Dulbecco's Modified Eagle Medium (DMEM) with 41 
1 mM CaCl2 for 10 to 15 minutes and collagenase activity was stopped by adding an equal 42 
volume of cold medium containing 10% fetal bovine serum (FBS). Following mechanical 43 
disruption, the cell suspension was filtered through a 70µm pore nylon mesh and then spun at 44 
50g/5 minutes 3 times at 4°C before the cell pellets were collected. Cell number and viability 45 
were determined by trypan blue exclusion using a Lecia DMIL inverted microscope (Leica 46 
Microsystems, Wetzlar, Germany). Average cell yield was 1,29 x 10
6
 ± SEM 193,540 cell 47 
per gm of liver tissue. Specimens with cell viability >85% by were chosen for subsequent 48 
experiments. Cells were plated at density of 1.5 – 2.5 x10
5
 cell cm
-1
 on mouse collagen type 49 
IV gel layer 1 - 2.5µg cm
-2 
(Corning Ltd., Flintshire, UK) in William’s E medium 50 
supplemented with 5% FBS (to facilitate cell adhesion) in Plating Supplement Pack (Thermo 51 
Fisher, Inchinnan, UK) and incubated at 37°C in a humidified incubator with 5% CO2. 6 – 12 52 
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hours later, medium (containing non-attached hepatocytes) was aspirated and cells were 53 
maintained in William’s E medium supplemented with serum free Maintenance Supplement 54 
Pack (Thermo Fisher). Medium has been changed every 3 days. 55 
 56 
5-Bromo-2’-deoxyuridine (BrdU) DNA incorporation assay: 57 
EGF (Sigma, Gillingham, UK) at 5, 10 and 20ng ml
-1
 or VIP (Sigma) at 10
-8
, 10
-7
 or 10
-6
M 58 
was added to the medium 24 hours following cell seeding. Assays were performed in 59 
quadruplicates. Hepatocytes were incubated with BrdU (10µg ml
-1
, Sigma) for 2 hours at 60 
37°C. Cells were washed for 5 minutes with Phosphate buffered saline (PBS) 3 times and 61 
fixed with ice-cold methanol for 30 minutes at 4°C. The nuclear membrane was 62 
permeabilised by using 2M HCl for 30 min at 37°C and acid was neutralised using an equal 63 
volume of 0.1M sodium borate for 2 minutes. Non-specific reactivity was blocked with 5% 64 
Donkey Serum in PBS with 0.1% Triton-X  (PBS-T) for 30 minutes at room temperature and 65 
then washed as before with 1 x PBS-T. Rat anti-BrdU antibody (Bio-Rad, Hertfordshire, UK) 66 
was used to detect DNA-integrated BrdU, 1µg ml
-1
 in PBS-T for 1 hour at room temperature 67 
and subsequently donkey anti-rat IgG-Alexa 488 (Thermo Fisher) 4µg ml
-1 
in PBS-T. Cells 68 
were incubated with 1µg ml
-1
 4'-6-diamidino-2-phenylindole, DAPI (Sigma) in water for 5 69 
minutes in the dark and washed with PBS, then analysed by fluorescence microscopy. The 70 
numbers of BrdU
+ 
cells were determined in 6 different high power fields per well against 71 
DAPI
+
 cells using an inverted Olympus IX81 fluorescent microscope with Olympus 72 
xcellence software version 01.2 (Olympus Life Science Solutions, Tokyo, Japan). 73 
 74 
Measurement of lactic dehydrogenase (LDH): 75 
Aliquots of substrate solution [100µl INT + P-Iodonitrotetrazolium Violet (33mg ml
-1
 in 76 
DMSO) + 100µl PMS, Phenazine methosulfate (9 mg ml
-1
) + 2.3 ml β-nicotinamide adenine 77 
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dinucleotide (NAD) hydrate (3.74 mg ml
-1
)] were freshly prepared. Equal volumes of 200mM 78 
Tris (hydroxymethyl)aminomethane (Tris) pH 8, 50mM Lithium lactate, substrate solution 79 
and samples or positive control (5µg ml
-1
 L-Lactic Dehydrogenase from bovine heart) were 80 
loaded into an assay plate. The Vmax was measured at 490nm for 10min. LDH activity (U ml
-
81 
1
) and LDH release in the supernatants (expressed as percentage of total cellular LDH 82 
activity) were calculated. 83 
 84 
Viability assay: 85 
Viability was determined using a colourimetric MTT assay (Sigma) according to the 86 
manufacturers instruction. Cells (2x10
5 
cell/well) were seeded in duplicate into 96-well plates 87 
and treated with various concentrations of EGF or VIP for 3 or 5 days. Viable cells were 88 
detected by measuring the absorbance at 570nm in a SpectraMax® Plus 384 Microplate 89 
Reader (Molecular Devices, Wokingham, UK). The water-soluble tetrazolium salts (WST-1) 90 
Quick Cell Proliferation Assay kit II (Abcam, Cambridge, UK) were used according to 91 
manufacturer instructions. Absorbance was detected at 440nm. 92 
 93 
Total RNA extraction and Reverse Transcription Polymerase Chain Reaction (RT-94 
PCR): 95 
RNA extraction was performed using a microspin column extraction kit (RNeasy® mini kit) 96 
(Qiagen, Crawley, West Sussex, UK) following the manufacturer’s instructions. RNA 97 
quantity and purity was assessed using a NanoDrop® ND-1000 spectrophotometer (Thermo 98 
Scientific). The ratio of 260nm and 280nm absorbance readings (A260/A280) of 1.8 to 2.0 99 
was considered as an acceptable indicator of nucleic acid purity. Complementary DNA 100 
(cDNA) was synthesised using a Primer Design Precision nanoScript 2 reverse transcriptase 101 
kit (Millbrook, Southampton, UK) according to the manufacturer’s instructions in a 102 
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MasterCycler® 480 thermocycler (Eppendorf, Hamburg, Germany). The cDNA was stored at 103 
-20ºC until use. 104 
 105 
Polymerase chain reaction (PCR) and Real time PCR (rt-PCR): 106 
The rt-PCR Primers were designed using the ProbeFinder software v2.5 107 
(Lifescience.roche.com) 
2
. Oligonucleotide primers were obtained from Eurofins 108 
MWG/operon (Ebersberg, Germany) and their sequences as following: Human Albumin 109 
(NM_000477.5) F: 5’-GTGAGGTTGCTCATCGGTTT -3’ and R: 5’-110 
GAGCAAAGGCAATCAACACC -3’), Antigen Identified By Monoclonal Antibody Ki-67, 111 
MKI-67 (NM_002417.4) F: 5’-TCAAGGAACTGATTCAGGAGAAG -3’ and R: 5’-112 
GTGCACTGAAGAACACATTTCC-3’), Histone Cluster 3, H3 (NM_003493.2) F: 5’-113 
GAGCTGCTAATCCGCAAGTT -3’ and R: 5’-GCGCAGGTCGGTCTTAAA -3’), 114 
Vasoactive Intestinal Peptide Receptor 1, VIP and pituitary adenylate cyclase-activating 115 
polypeptide receptor-1 (VPAC1) 
3
 (NM_004624) F: 5’-116 
CTTCTGGTCGCCACAGCTATCCTG -3’ and R: 5’- 117 
ACTGCTGTCACTClTCCTGATATC-3’), Epidermal Growth Factor Receptor, Epidermal 118 
Growth Factor Receptor (EGFR)  (NM_005228.3) F: 5’-TTCCTCCCAGTGCCTGAA -3’ 119 
and R: 5’- GGGTTCAGAGGCTGATTGTG -3’) and Glycerinadehyde-3-Phosphate-120 
Dehydrogenase, GAPDH (NM_002046) F: 5’- GATGACATCAAGAAGGTGGTG-3’ and R: 121 
5’- GCTGTAGCCAAATTCGTTGTC-3’). Level of VPAC1 and EGFR mRNA expression 122 
was assessed using GoTaq® Hot Start Polymerase (Promega UK Ltd, Southampton, UK) 123 
according to manufacturer instructions. PCR conditions were 2 minutes at 95°C, and 124 
followed by 35 PCR cycles of 60 seconds at 95°C, 60 seconds at 60°C and 60 seconds at 125 
72°C. PCR products were visualized on 2% agarose gel, band density were measured and 126 
normalised to that of GAPDH using a ChemiDoc™ imaging system (Bio-Rad). The total 127 
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reaction volume was 10µl of 2x qPCR SYBR green Mastermix buffer (Primer Design), 128 
primer pairs and cDNA template were mixed and PCR products were detected in an A&B 129 
7900HT Fast Real-Time PCR System thermocycler (Applied Biosystems, CA, USA). PCR 130 
conditions were 10 min at 95°C, and followed by 40 PCR cycles of 15 seconds at 95°C and  131 
60 seconds at 60°C. All assays were performed in triplicates. The melting curve was 132 
generated with a stepped temperature transition from 60 to 95°C with a rise of 1°C/5 sec for 133 
each step. The Ct values were normalized to the GAPDH housekeeping gene
4
 and calibrated 134 
to untreated cells. The relative quantification (RQ), expressed as fold change, was calculated 135 
according to the ∆∆Ct method.  136 
 137 
Detection of Phospho-p44/42 MAPK (Erk1/2) and VPAC1 in hepatocytes: 138 
Gel electrophoresis: 139 
Hepatocytes were serum starved for 24 hour following 12 to 16 hours of attachment. Then 140 
incubated with EGF (20 ng ml
-1
) or VIP (10
-6
 M). To block B-RAF protein or cAMP cells 141 
were incubated with SB-590885 or Rp-Adenosine 3’, 5’-cyclic monophosphorothioate 142 
triethylammonium salt (Rp-cAMPS) inhibitors. Cells were lysed using 1x TruPAGE™ LDS 143 
Sample Buffer [with 2mM Sodium orthovanadate (Na2VO3), 20mM Sodium Pyrophosphate 144 
(Na4P2O7), 1mM ethylenediaminetetraacetate (EDTA), 1mM EGTA and 0.5µg ml
-1
 145 
Leupeptin] and run a TruPAGE® 10% precast gels (Sigma) under reducing conditions. Total 146 
protein concentrations were measured using bicinchoninic acid (BCA) colorimetric protein 147 
assay kit (Sigma) in accordance with the manufacturer’s instructions using a BSA standard. 148 
Western blotting: 149 
Proteins were transferred to nitrocellulose membranes by a wet transfer method. Membranes 150 
were blocked for 1 hour in 5% non-fat blotting grade cow’s milk (Bio-Rad) in 0.05 % Tris-151 
buffered saline (TBS)–Tween® 20 solution. The membranes were then probed with 1:1000 152 
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rabbit anti-human Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (New England 153 
Biolabs, Hertfordshire, UK) or 1:000 rabbit anti-human p44/42 MAPK (Erk1/2) antibody 154 
(New England Biolabs) overnight at 4°C, followed by goat anti-rabbit-horseradish peroxidase 155 
(HRP) (DakoCytomation, Cambridgeshire, UK) at a dilution of 1:2000 for 45 minutes. 156 
Reactive bands were visualised using the Luminata Forte Western HRP substrate 157 
chemiluminescent substrate (Millipore UK Ltd., Hertfordshire, UK) in a ChemiDoc™ 158 
imaging system (Bio-Rad). In another experiment, level of VPAC1 protein expression in 159 
untreated or VIP (10-6 M) treated hepatocytes, was investigated using a rabbit polyclonal anti 160 
VPAC1 (Abcam) and followed by goat anti-rabbit-horseradish peroxidase (HRP) 161 
(DakoCytomation) as before. 162 
 163 
cAMP Direct Immunoassay: 164 
Levels of cAMP in hepatocytes at 24 h following cell seeding (day 0) and at day 3 or 5 165 
following stimulation with 10
-6
 M VIP were detected using a cAMP direct immunoassay 166 
(Abcam) according to the manufacturer’s instructions. Absorbance reading were determined 167 
at 450 nm and cAMP concentrations (µM) were calculated by plotting values against cAMP 168 
standard (0-0.25 µM) following background subtraction. cAMP concentrations (µM) were 169 
determined and corrected to total proteins concentrations in samples (µg). 170 
 171 
Albumin ELISA: 172 
Albumin concentrations in the supernatant of hepatocytes cultures was determined using the 173 
ELISA DuoSET
®
 kit for human albumin (R&D Systems, Oxfordshire, UK) according to 174 
manufacturer’s instructions. Absorbance values were detected at 450nm with subtraction of 175 
readings at 570nm to compensate for optical interference on a microplate Reader. The 176 
detection range was from 2.5 to 160ng ml
-1
. 177 
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Urea concentration assay: 178 
The QuantiChrom™ urea assay kit (QuantiChrom, BioAssay Systems, Hayward, CA) was 179 
used according to the manufacturer’s instructions. Following 20 minutes incubation at room 180 
temperature, Absorbance at 430nm was measured and concentration of urea of the sample 181 
against 5mg dl
-1
 standard was calculated in mg dl
-1
.  182 
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Supplementary Figure 1 The effect of VIP on VPAC1 mRNA gene expression in 
hepatocytes. n = 3 for each condition. P values shown in the graph are for overall 
comparison with hepatocytes at day 1 of treatment. * P<0.05. Mean ± SEM. Two-way 
ANOVA followed by Fisher's least significant difference (LSD). 
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Supplementary Figure 2 Albumin production from human hepatocytes cultured with 
EGF and VIP. Hepatocytes were cultured in William’s E maintenance medium and EGF (5, 
10 or 20 ng ml-1) and VIP (10
-6
 M) was added one day later. n = 3 for each condition. P values 
shown in the graph are for comparison at individual concentrations. * P<0.05, ** P<0.005, 
*** P<0.0005, **** P<0.0001.  Mean ± SEM. Two-way ANOVA followed by Fisher's least 
significant difference (LSD). 
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